Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent, Umn Pharma in Biosimilar Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Catalent, Umn Pharma in Biosimilar Pact

Will use GPEx technology to produce cell lines

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions has signed an agreement with UMN Pharma, Inc. to provide a broad range of biosimilar cell lines using its GPEx technology. UMN and its subsidiary Unigen, will produce a number of biosimilars using Catalent’s GPEx cell lines. UMN will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales. UMN plans to begin multiple biosimilar projects through alliances for the Asian market.
 
“There are great synergies between UMN Pharma and Catalent in terms of technologies, business structure, speed and culture,” said Masahiro Michishita, executive chairman of UMN Pharma. “Harnessing Catalent’s broad biologics development and cell construction expertise gives UMN Pharma a unique platform to grow our biosimilars business globally.”
 
Barry Littlejohns, Catalent’s business unit president, said, “This agreement will allow Catalent to continue to grow its biologics development and manufacturing interests of multiple biosimilars and NBEs, particularly in the Asian market. UMN Pharma’s ambitious expansion plans reflect Catalent’s strategy for growth in what we consider to be a key market.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics